Clinical trial results found that a new antibiotic candidate could shorten TB treatment from the standard 6 months to 8 weeks ...

The Global TB Report 2025 released by the World Health Organization (WHO) highlights that India’s TB incidence has reduced ...

New clinical trial results presented by TB Alliance at the Union World Conference on Lung Health show that the novel ...

An international team of investigators today announced promising data from a trial of a novel antibiotic that could ...

While the recognition of innovations such as point-of-care diagnostics is heartening, the bigger picture must not be lost ...

Tuberculosis (TB) is one of the world's most common infectious diseases. Although infection with the Mycobacterium ...

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today applauded a commitment by world leaders attending the first-ever high-level United ...

Tuberculosis (TB) remains one of humanity’s oldest and most persistent health challenges. Despite significant medical advances, this infectious disease continues to affect millions globally, with ...

Despite strong national programmes, late diagnosis, treatment gaps, private-sector fragmentation, and poor adherence remain ...

The Department of Health (DOH) and the World Health Organization (WHO) are ramping up efforts to eliminate tuberculosis (TB) ...

This milestone reflects nearly two years of coordinated public health response, with no new patients diagnosed with Active TB ...

A 3-month, 12-dose regimen of rifapentine and isoniazid (INH) was less toxic, had better compliance, and showed similar efficacy as 6 months of INH alone in preventing tuberculosis (TB) in people with ...